REG - Shield Therapeutics - Q3 2025 Trading Update

Shield TherapeuticsAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251023:nRSW5478Ea&default-theme=true

RNS Number : 5478E  Shield Therapeutics PLC  23 October 2025

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulation
(EU) No. 596/2014 (as it forms part of domestic law in the United Kingdom by
virtue of the European Union (Withdrawal) Act 2018). Upon the publication of
this announcement via the Regulatory Information Service, this inside
information is now considered to be in the public domain.

 

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

 

Q3 2025 Trading Update

Strongest quarterly performance to date with c. 15% ACCRUFeR® prescription
growth over Q2 2025

c. 54,000 ACCRUFeR® prescriptions with

$13.1m net revenues and an average net selling price of $237

Guidance remains to turn cash flow positive by the end of 2025

 

London, UK, 23 October 2025: Shield Therapeutics plc (LSE: STX), a
commercial-stage pharmaceutical company specialising in iron deficiency,
provides an unaudited Q3 2025 trading update.

 

In the third quarter of 2025, Shield reported unaudited ACCRUFeR® net
revenues of $13.1m, c. 54,000 total prescriptions and an average net selling
price of $237, this compared to $7.2m, c. 44,000 and $167 respectively in Q3
2024. Given the strong momentum entering Q4 2025 with September generating
>40% of Q3 2025 revenues, the Company remains on track to achieve its prior
guidance of turning cash flow positive by the end of 2025.

Q3 2025 Key Business Metrics:

·    ACCRUFeR® net revenue of $13.1m (Q2 2025: $12.8m and Q3 2024:
$7.2m).

·    ACCRUFeR® average net selling price of $237 (Q2 2025: $231 and Q3
2024: $167).

·    ACCRUFeR® prescriptions of c. 54,000, with c. 22% consignment-based
prescriptions that were dispensed at a significantly subsidised price to
patients and were not yet reimbursed by payors.

·    Cash and cash equivalents of $8.6m as of 30 September 2025 ($10.8m as
of 30 June 2025) including receipt of net proceeds from placing announced in
the period.

·    The company remains on track to turn cash flow positive by the end of
2025

Anders Lundstrom, Chief Executive Officer, commented: "I am very pleased to
see ACCRUFeR®'s strong performance continue into Q3 2025. The combined
efforts of the Shield and Viatris Sales team along with our strategic
marketing initiatives have driven continued strong performance in Q3, marking
our strongest quarter on record with a new high in prescription volumes, net
selling price, and revenues. This was further underscored in September, which
delivered the highest net revenue month to date representing >40% of the Q3
ACCRUFeR® revenues. This performance has reinforced our alignment with
full-year performance targets enabling us to stay on track to turning cash
flow positive by the end of 2025"

 

Investor Presentation via Investor Meet Company

 

CEO, Anders Lundstrom, and CFO, Santosh Shanbhag, will be hosting a live
online presentation relating to the Q3 2025 Trading Update via the Investor
Meet Company platform at 3:00 pm (BST) on 23 October 2025.

 

The presentation is open to all existing and potential investors. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until
2.00 pm (BST) or at any time during the live presentation. Investors can sign
up to Investor Meet Company for free and add to meet Shield Therapeutics plc
via:

https://www.investormeetcompany.com/shield-therapeutics-plc/register-investor
(https://www.investormeetcompany.com/shield-therapeutics-plc/register-investor)

 

Investors who already follow Shield Therapeutics plc on the Investor Meet
Company platform will automatically be invited.

 

For further information please contact:

 Shield Therapeutics plc                                                                        www.shieldtherapeutics.com (http://www.shieldtherapeutics.com/)
 Anders Lundstrom, CEO                                                                          +44 (0) 191 511 8500

 Santosh Shanbhag, CFO                                                                          Investorrelations@shieldtx.com

 Stephanie Hicks, Investor Relations

 Nominated Adviser and Joint Broker

 Peel Hunt LLP
 James Steel                                                                                    +44 (0)20 7418 8900
 Joint Broker

 Cavendish Ltd

 Geoff Nash/ Isaac Hooper/Nigel Birks/Harriet
 Ward

                                                                                                +44 (0)20 7220 0500

About Iron Deficiency and ACCRUFeR®/FeRACCRU®

Clinically low iron levels (aka iron deficiency, ID) can cause serious health
problems for adults of all ages, across multiple therapeutic areas. Together,
ID and ID with anemia (IDA) affect about 20 million people in the US and
represent a $2.3B market opportunity. As the first and only FDA approved oral
iron to treat ID/IDA, ACCRUFeR® has the potential to meet an important unmet
medical need for both physicians and patients and is now the leading #1
branded prescription oral iron the market today for ID/IDA (data source -
IQVIA Xponent PlanTrak).

ACCRUFeR®/FeRACCRU® (ferric maltol) is a novel, stable, non-salt-based oral
therapy for adults with ID/IDA. The drug has a novel mechanism of absorption
compared to other oral iron therapies and has been shown to be an efficacious
and well-tolerated therapy in a range of clinical trials. More information
about ACCRUFeR®/FeRACCRU®, including the product label, can be found at:
www.accrufer.com (http://www.accrufer.com) and www.feraccru.com
(http://www.feraccru.com) .

 

About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company that delivers
ACCRUFeR®/FeRACCRU® (ferric maltol), an innovative and differentiated
pharmaceutical product, to address a significant unmet need for patients
suffering from iron deficiency, with or without anemia. The Company has
launched ACCRUFeR® in the U.S. with an exclusive, multi-year collaboration
agreement with Viatris. Outside of the U.S., the Company has licensed the
rights to five specialty pharmaceutical companies. FeRACCRU® is
commercialised in the UK and European Union by Norgine B.V., which also has
marketing rights in Australia and New Zealand. Shield also has an exclusive
license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the
development and commercialisation of ACCRUFeR®/FeRACCRU® in China, Hong
Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea,
with Kye Pharmaceuticals Inc. for Canada, and with VITAL-NET for Japan.

 

ACCRUFeR®/FeRACCRU® has patent coverage until the mid-2030s.

ACCRUFeR®/FeRACCRU® are registered trademarks of Shield Therapeutics.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTPKNBPPBDKBKB



            Copyright 2019 Regulatory News Service, all rights reserved